Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Neogenomics Inc (NASDAQ: NEO) closed at $7.13 down -3.39% from its previous closing price of $7.38. In other words, the price has decreased by -$3.39 from its previous closing price. On the day, 1.95 million shares were traded.
Ratios:
For a deeper understanding of Neogenomics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.94 and its Current Ratio is at 2.05. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.45.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 27 ’25 when Kelly Michael Aaron bought 5,000 shares for $7.60 per share. The transaction valued at 38,000 led to the insider holds 5,000 shares of the business.
Stone Warren bought 5,700 shares of NEO for $48,895 on May 12 ’25. The Pres & Chief Operating Officer now owns 108,280 shares after completing the transaction at $8.58 per share. On May 09 ’25, another insider, TETRAULT LYNN A., who serves as the Director of the company, bought 7,000 shares for $8.14 each. As a result, the insider paid 56,974 and bolstered with 7,000 shares of the company.
Stock Price History:
Over the past 52 weeks, NEO has reached a high of $19.11, while it has fallen to a 52-week low of $6.08. The 50-Day Moving Average of the stock is -15.49%, while the 200-Day Moving Average is calculated to be -45.30%.
Shares Statistics:
A total of 128.36M shares are outstanding, with a floating share count of 127.02M. Insiders hold about 1.30% of the company’s shares, while institutions hold 98.82% stake in the company.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 13.0 analysts currently analyzing and rating the stock of Neogenomics Inc (NEO).The consensus estimate for the next quarter is $0.05, with high estimates of $0.08 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.22 and $0.11 for the fiscal current year, implying an average EPS of $0.16. EPS for the following year is $0.31, with 13.0 analysts recommending between $0.4 and $0.21.
Revenue Estimates
A total of 13 analysts believe the company’s revenue will be $183.06M this quarter.It ranges from a high estimate of $189.26M to a low estimate of $179.8M. As of the current estimate, Neogenomics Inc’s year-ago sales were $164.5MFor the next quarter, 13 analysts are estimating revenue of $192.82M. There is a high estimate of $197M for the next quarter, whereas the lowest estimate is $186.55M.
A total of 14 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $753.02M, while the lowest revenue estimate was $731.58M, resulting in an average revenue estimate of $745.63M. In the same quarter a year ago, actual revenue was $660.57MBased on 14 analysts’ estimates, the company’s revenue will be $829.94M in the next fiscal year. The high estimate is $840.3M and the low estimate is $814M.
